HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hazenberg, B. P.C. Articles by Jager, P. L. Search for Related Content PubMed PubMed Citation Articles by Hazenberg, B. P.C. Articles by Jager, P. L.

Diagnostic Performance and Prognostic Value of Extravascular Retention of ¹²³I-Labeled Serum Amyloid P Component in Systemic Amyloidosis

¹ Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; ² Department of Nuclear Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; ³ Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and ⁴ Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

View larger version (18K): [in this window] [in a new window]   FIGURE 1.  PSDI and EVR24 of all 167 patients with systemic amyloidosis (AA, AL, and ATTR types). Patients are subdivided according to intensity of scintigraphic uptake, represented by x (negative, n = 28), (score 1+, n = 45), (score 2+, n = 32), and • (score 3+, n = 62). Dotted lines are reference limits of controls (>0.51 for PSDI and <50% for EVR24), resulting in reference area in upper left quadrant.

View larger version (12K): [in this window] [in a new window]   FIGURE 2.  Relationship between EVR24, serum alkaline phosphatase (A), and endogenous creatinine clearance (B) in patients with AL amyloidosis. Solid lines are linear regression lines.

View larger version (10K): [in this window] [in a new window]   FIGURE 3.  Five-year survival of 80 patients with AL amyloidosis. (A) Patients with (dotted line) and without (solid line) clinical involvement of heart. (B) Patients with high (>50%) (•) and with low (<50%) () EVR24. (C) Patients stratified according to high (>50%) (•) and low (<50%) () EVR24 and presence (dotted line) or absence (solid line) of clinical involvement of heart.